Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices
Creators: name: Lyons, Roger M.
name: Aguilar, Kathleen M.
name: Sudharshan, Lavanya
name: Venkatasetty, Divea
name: Ndukum, Juliet
name: Zackon, Ira
name: Yu, Jingbo
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Cell Biology
subject: Pharmacology
subject: Biotechnology
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Hematology
subject: Infectious Diseases
subject: FOS: Health sciences

description: This study aimed to describe clinical characteristics—including blood counts and pharmacologic cytoreductive treatment patterns—and outcomes after 6 months of hydroxyurea (HU) treatment among patients with polycythemia vera (PV) in US community practices. This retrospective observational study included adult patients with a PV diagnosis (1JAN2008–31JAN2020) and ≥2 postdiagnosis visits in the iKnowMed electronic health record database (US Oncology Network and non-Network clinics). Suboptimal HU response required ≥1 criterion after ≥3 months of treatment: white blood cell count (WBC) &gt;10 × 10<sup>9</sup>/L, platelet count &gt;400 × 10<sup>9</sup>/L, and/or hematocrit &gt;45%. Patient characteristics were summarized from structured data using descriptive statistics; overall survival was assessed by Kaplan–Meier method. Among 5871 patients, mean age at diagnosis was 66.1 years (69.8% ≥60 years); 67.2, 59.4, 38.2, and 33.9% of patients had elevated hematocrit, hemoglobin, WBC, and platelets, respectively; 6.1% had a previous thrombotic event. Of 4185 (71.3%) high-risk and 1675 low-risk patients, 55.0 and 32.0% received pharmacologic cytoreductive treatment, most commonly HU (89.8 and 88.9%). After 6 months of pharmacologic cytoreductive treatment, 56.9% had a suboptimal response. Five-year survival probability was 81.5 and 84.3% among patients with suboptimal and optimal responses to HU, respectively, which was not statistically different but suggests potential for survival benefits with longer follow-up. Nearly half of high-risk patients with PV did not receive pharmacologic cytoreductive treatment. Of those who did, over half had suboptimal response, suggesting these patients may need dose adjustments, improved adverse effect management, or alternative treatments. Longer follow-up may be needed to assess an association between HU response and survival. Polycythemia vera (PV) is a rare blood cancer that causes an overproduction of blood cells. The aim of treatment is to reduce the number of blood cells and prevent blood clots. Hydroxyurea is a drug often used for treatment, but it does not work for all patients and the side effects can lead some patients to discontinue treatment. For this analysis, the authors looked at health records of almost 6000 patients with PV who were treated in community practices in the United States between 2008 and 2020. The study found that after 6 months of receiving hydroxyurea, blood cell numbers remained elevated in over half of the patients, indicating the treatment was inadequate. This finding suggests that patients with PV may need medication dosage adjustments, improved management of their treatment side effects, or alternative treatments sooner than is currently common.